A Look At Sarepta Therapeutics (SRPT) Valuation As EMBARK Phase 3 ELEVIDYS Readout Nears

Simply Wall St.

Jan 26

AdvertisementEMBARK readout puts ELEVIDYS back in focus Sarepta Therapeutics (SRPT) is back on investor radars after the company scheduled a January 26 webcast to share 3 year topline functional ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2606264795"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2606264795\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2606264795?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-01-26 07:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606264795","market":"hk","top_or_hot":-1,"title":"A Look At Sarepta Therapeutics (SRPT) Valuation As EMBARK Phase 3 ELEVIDYS Readout Nears","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementEMBARK readout puts ELEVIDYS back in focus Sarepta Therapeutics (SRPT) is back on investor radars after the company scheduled a January 26 webcast to share 3 year topline functional ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/a-look-at-sarepta-therapeutics-srpt-valuation-as-embark-phas\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Sarepta Therapeutics (SRPT) Valuation As EMBARK Phase 3 ELEVIDYS Readout Nears</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Sarepta Therapeutics (SRPT) Valuation As EMBARK Phase 3 ELEVIDYS Readout Nears\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-26 07:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/a-look-at-sarepta-therapeutics-srpt-valuation-as-embark-phas><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementEMBARK readout puts ELEVIDYS back in focus Sarepta Therapeutics (SRPT) is back on investor radars after the company scheduled a January 26 webcast to share 3 year topline functional ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/a-look-at-sarepta-therapeutics-srpt-valuation-as-embark-phas\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0002141913.USD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/a-look-at-sarepta-therapeutics-srpt-valuation-as-embark-phas","article_id":"2606264795","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/a-look-at-sarepta-therapeutics-srpt-valuation-as-embark-phas","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2606264795","pubTimestamp":1769382940,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"EMBARK readout puts ELEVIDYS back in focus\nSarepta Therapeutics (SRPT) is back on investor radars after the company scheduled a January 26 webcast to share 3 year topline functional outcomes from the EMBARK Phase 3 ELEVIDYS trial in Duchenne muscular dystrophy.\nSee our latest analysis for Sarepta Therapeutics.\nAt a share price of US$21.13, Sarepta’s recent performance has been weak, with a 30 day share price return of 4.5% decline and a 1 year total shareholder return of 81.9% loss. This...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4585":"ETF&股票定投概念","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4139":"生物科技","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","SRPT":"Sarepta Therapeutics","IE0009355771.USD":"骏利亨德森环球生命科技A Acc"},"translate_title":"随着第3阶段ELEVIDYS读数的临近，Sarepta Therapeutics(SRPT)的估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRPT":1.5},"content_text":"AdvertisementEMBARK readout puts ELEVIDYS back in focus Sarepta Therapeutics (SRPT) is back on investor radars after the company scheduled a January 26 webcast to share 3 year topline functional outcomes from the EMBARK Phase 3 ELEVIDYS trial in Duchenne muscular dystrophy. See our latest analysis for Sarepta Therapeutics. At a share price of US$21.13, Sarepta’s recent performance has been weak, with a 30 day share price return of 4.5% decline and a 1 year total shareholder return of 81.9% loss. This suggests momentum has been fading even as investors refocus on EMBARK and earlier safety concerns around ELEVIDYS. If you are watching how events like the EMBARK readout can reshape expectations in drug development, it may be a good moment to scan other healthcare stocks for comparison. With the share price far below its recent history and ELEVIDYS still central to the story, is Sarepta now trading at a discount to its genetic medicines pipeline, or is the market already pricing in whatever comes next? Most Popular Narrative: 2.5% Overvalued The most followed narrative puts Sarepta Therapeutics’ fair value at $20.61, slightly below the last close of $21.13, framing a tight valuation gap.  The analysts have a consensus price target of $23.96 for Sarepta Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $80.0, and the most bearish reporting a price target of just $5.0.  Read the complete narrative. Want to see what sits behind that tight fair value range? This narrative leans on shifting revenue expectations, improving margins and a future earnings multiple that assumes a very specific path. Curious which levers matter most here and how they interact over time? The full story connects those moving parts into one valuation view. Result: Fair Value of $20.61 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, safety scrutiny around ELEVIDYS, along with any further hurdles in payer coverage or treatment logistics, could quickly challenge this tight fair value story. Find out about the key risks to this Sarepta Therapeutics narrative. Another View: Cash Flows Point a Very Different Way While the crowd narrative has Sarepta at roughly 2.5% overvalued around a fair value of $20.61, our DCF model lands in a very different place. On that method, the estimated future cash flow value is $76.06, with the current price of $21.13 trading at about a 72.2% discount. Which perspective aligns more closely with the level of risk you are willing to take? Look into how the SWS DCF model arrives at its fair value. SRPT Discounted Cash Flow as at Jan 2026 Build Your Own Sarepta Therapeutics Narrative If you look at this and think the assumptions miss something, or simply prefer to work from your own inputs and data, you can build a version that reflects your view in just a few minutes: Do it your way. A great starting point for your Sarepta Therapeutics research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision. Looking for more investment ideas? If Sarepta has your attention, do not stop here. Broaden your opportunity set with a few focused stock ideas that match different parts of your watchlist.  Spot potential mispricings by hunting for companies our models flag as attractively valued through these 871 undervalued stocks based on cash flows built around cash flow strength. Ride breakthroughs in automation and machine learning by checking out these 23 AI penny stocks that are tied to real business fundamentals instead of just headlines. Turn income goals into a practical shortlist by scanning these 13 dividend stocks with yields > 3% that already clear a 3% yield hurdle.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}